Group 1 - The company Changjiang Life Sciences Technology (00775.HK) announced the sale of its melanoma vaccine business to TransCode Therapeutics for $125 million (approximately HKD 975 million) [1] - The transaction will be paid through the issuance of consideration shares by the buyer, with additional milestone payments of up to $95 million (approximately HKD 741 million) upon achieving certain milestones [1] - The seller will acquire approximately 9.1% of the buyer's ordinary shares after the issuance of payment shares, and up to approximately 90.7% after the conversion of preferred shares [1] Group 2 - The target company, Polynoma, is a Delaware limited liability company that focuses on the research, production, and commercialization of melanoma treatment drugs [2] - Polynoma's flagship candidate drug, seviprotimut-L, is a proprietary multi-valent melanoma cancer vaccine [2] - After the transaction, the seller will no longer hold any equity in the target company, which will cease to be a subsidiary of the seller [2] Group 3 - The merger between Polynoma and the buyer is expected to create synergies between their businesses, addressing significant unmet needs in oncology [3] - The buyer's product line includes TTX-MC138, currently in Phase I/II clinical trials, and other preclinical candidates, complementing Polynoma's advanced candidate [3] - The buyer, being a NASDAQ-listed entity, will enhance the market exposure of seviprotimut-L and improve fundraising and partnership opportunities for accelerated development [3]
长江生命科技(00775.HK)拟出售癌症疫苗业务并换取买方股权及里程碑付款